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Abstract: The phenomenon of accelerated tumor growth following surgery has been
observed repeatedly and merits further study. Inflammatory breast carcinoma (IBC) is widely
recognized as an extremely aggressive malignancy characterized by micrometastasis at
the time of diagnosis, with one interesting subgroup defined as secondary IBC where
pathologically identifiable IBC appears after surgical treatment of a primary non-inflammatory
breast cancer. One possible mechanism can be related to the stimulation of dormant
micrometastasis through local angiogenesis occurring as part of posttraumatic healing. In
this report, we review cases of secondary IBC and others where localized trauma was
followed by the appearance of IBC at the traumatized site that have been identified by our
IBC Registry (IBCR) and hypothesize that angiogenesis appearing as part of the healing
process could act as an accelerant to an otherwise latent breast malignancy. It is therefore
possible that secondary IBC can be used as a model to support local angiogenesis as an
important contributor to the development of an aggressive cancer.
Keywords: surgery; inflammatory breast cancer; trauma; secondary IBC; dormant
micrometastasis; IBC registry; angiogenesis
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1. Introduction
Inflammatory breast cancer (IBC) is widely recognized as an extremely aggressive malignancy that
is usually characterized by micro-metastases at the time of diagnosis. IBC is characterized clinically as
a rapidly growing tumor with skin manifestation of erythema, warmth and edema and pathologically
by invasion of the dermal lymphatics with tumor microemboli. In 1938, Taylor and Meltzer described
two types of IBC, the primary form, where the characteristic clinical features were prominent from the
outset and the secondary form, where the clinical features appeared subsequent to treatment for a primary
non-inflammatory breast cancer [1].
IBC affects approximately 2.5% of women with breast cancer annually in the United States and thus
affects more than 4,800 women each year, more than twice as many as those developing chronic
myelocytic leukemia or acute lymphocytic leukemia [2]. It is a clinically and pathologically distinct
form of breast cancer that is particularly fast growing, highly angiogenic and angioinvasive with its
aggressiveness and angiogenicity present from its inception. The precise case definition is controversial [2],
with the American Joint Committee on Cancer (AJCC) focusing on a clinical case definition [3], and
the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute
focusing primarily on a pathological case definition [4]. While the typical patient presents with pain
and a tender, firm enlarged breast with the symptoms developing in less than six months, IBC may be
diagnosed with less than half of the breast involved and without the pathological confirmation of
dermal lymphatic invasion [2,5]. The skin over the breast is reddened, warm, thickened and often has a
pitted appearance termed “peau d’ orange”. The designation “inflammatory” stems from the clinical
appearance that mimics an acute inflammation, but this is somewhat of a misnomer [6]. Dermal
lymphatic occlusion by tumor infiltrate, a finding which pathologists rely upon to confirm their clinical
diagnosis, is believed to lead to increased vascular pressure and stasis, and inflammation does not
actually contribute in any consequential way to the skin manifestations [7]. Since IBC tumors produce
negligible amounts of most inflammatory cytokines, host inflammatory cells are rarely detected around
the tumor stroma [6].
The Inflammatory Breast Cancer Registry (IBCR) was developed to provide a standardized population
of IBC patients for epidemiologic and laboratory studies, and among the 156 patients enrolled thus far,
eight were identified as having secondary IBC. In our review of these cases and others where localized
trauma was followed by the appearance of IBC at the traumatized site, we hypothesized that
angiogenesis appearing as part of the healing process could act as an accelerant to an otherwise latent
breast malignancy. We present examples of this possible phenomenon which could suggest a
population of patients for further investigation.
2. Experimental Section
The Inflammatory Breast Cancer Registry (IBCR) was established 1 June 2002 to collect standardized
clinical data and biospecimens from patients with IBC in the United States and Canada [2]. Patients
with IBC who were entered into the Registry were at least 18 years of age, signed an Informed
Consent, agreed to be interviewed and to provide access to medical records and tissue blocks. Patients
contacted the Registry after learning about it on the internet or from local oncologists. It was funded
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initially by the Department of Defense and is now supported by laboratories that use the tissue samples
to characterize the disease. In this report we document the histories of two patients with secondary IBC
as well as two additional patients whose disease presentation also supports the possible occurrence of
IBC secondary to breast trauma. Secondary IBC cases were defined as women who have had surgery for
non-inflammatory breast cancer with recurrence manifest as skin erythema shown to be associated with
pathologically confirmed tumor emboli in the dermal lymphatics.
2.1. Case Reports
2.1.1. IBC 13—Secondary IBC
This 58 year old woman was diagnosed with Stage II infiltrating ductal carcinoma of the right
breast in November 1992. She had a modified radical mastectomy and lymph node dissection, three of
seventeen nodes being positive for tumor. She was treated with six months of cyclophosphamide,
methotrexate and 5-fluorouracil and had no evidence of recurrence. In January 2000 she had a second
right breast reconstructive operation and post-operatively redness was noted at the surgical scar site
which was first considered to be an allergic reaction and was not biopsied. In August 2000 she
developed axillary metastases and she was treated with herceptin, taxotere and carboplatin. While on
chemotherapy the redness progressively got worse and was eventually documented as being due to
dermal lymphatic invasion. In March 2002 she developed skin involvement of the left breast which
also showed dermal lymphatic invasion and she died in May 2008.
2.1.2. IBC 20—Secondary IBC
This 45 year old woman was noted to have a 3.5 cm mass with spiculated margins 13 June 2000.
One week later she was diagnosed as having an infiltrating ductal carcinoma and a lumpectomy was
subsequently performed. No skin involvement was observed. In July she had a right partial mastectomy
and there appeared to be a complete resection with adequate margins beyond the tumor. Three of
14 axillary lymph nodes were noted to be involved with tumor. The surgery was followed by
chemotherapy with adriamycin and cytoxan. Erythema of the skin first appeared in September 2000
and biopsy showed dermal lymphatic invasion with tumor microemboli. Despite treatment with Taxol
and a right total mastectomy which showed no residual tumor, she developed metastatic disease and
died in September 2003.
2.1.3. IBC 36—Post-Traumatic IBC
This 63 year old woman with a history of fibrocystic disease had a routine mammogram in
25 October 2000 which showed “fibrogandular elements” in the left breast. On clinical exam the left
breast seemed larger than the right and there was some flattening of the nipple. She had first noticed in
August 2000 some tenderness of the left breast and the breast felt engorged. An ultrasound was
performed which showed a small cyst in the retroareolar region with dilated retroareolar ducts. The
surgeon suggested a ductogram which was performed 18 December 2000 and showed evidence of a
filling defect in one of the ducts approximately 5 cm posterior to the areola. The patient described the
procedure as being extremely painful and subsequently she had constant pain in the left breast.
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Subsequently she awoke at night with breast engorgement and heaviness accompanied by nipple
inversion and she insisted on an evaluation and biopsy. A biopsy 15 January 2001 showed poorly
differentiated ductal carcinoma with extensive lymphatic carcinomatosis. On further evaluation one
week later the diagnosis of IBC was made based on erythema and some peau d’ orange under her
breast. She received three cycles of adriamycin and cytoxan with an immediate clinical response
followed by a left modified radical mastectomy performed on 30 March 2001 which showed a residual
mass with multifocal lymphatic involvement, including invasion of the dermal lymhatics. Surgery was
followed by a fourth cycle of adriamycin and cyclophosphamide, three cycles of Taxol and radiation
therapy which ended 30 August 2001. She was in clinical remission until December 2002 when she
developed a significantly elevated CA 15-3 and CEA and a nodule under her clavicle. Biopsy
documented metastatic disease and CT scan revealed bilateral pulmonary nodules. Total body scan
suggested metastatic disease in the hip. A left breast biopsy showed Her2/neu positive poorly
differentiated ductal carcinoma with extensive lymphatic carcinomatosis. She was started on herceptin
and taxotere which did not control her disease and she died in May 2003.
2.1.4. IBC 46—Post-Traumatic IBC
This 33 year old woman was in good health and was employed as a civilian working for the military
in Guam when she decided to have her nipples pierced. The procedure was performed in early 1999
and subsequently she noticed that the right nipple slowly began to swell. By the end of December the
swelling was very prominent and she had the ring removed. On 1 January 2000 she noted a large lump
behind the areola. She was able to get an ultrasound in Guam and noticed that the lump had doubled in
size in the next five days; she also developed pain with intermittent stinging sensations but no redness.
Her original Ob/Gyn doctor in Guam thought it to be an infection and put her on antibiotics. While
traveling back to the U.S. where she was hired for a job in Washington, DC, the patient developed
erythema of the entire breast with a thumb size port wine stain laterally. She noted that the lump was
now of the size of a grapefruit. On evaluation in the U.S. 28 January 2000 the right breast was noted to
be tender, painful and swollen with hyperemia, dermal thickening and induration especially in the
inferolateral breast. A mammogram that day showed only nonspecific changes suggestive of mastitis.
She was treated with antibiotics with no improvement. A biopsy of an indurated part of the port wine
stain documented a malignancy and the diagnosis of IBC was made. The mass grew quickly involving
more than half the breast with peau d’orange appearance and she received four cycles of adriamycin
and cytoxan with excellent response. Mastectomy performed in June 2000 showed infiltrating ductal
carcinoma with involved margins and dermal/lymphovascular invasion. All five lymph nodes
examined showed metastatic disease. In May 2001 she developed severe back pain and MRI suggested
lesions in C7 and T11. She was started on radiation therapy but in June she developed lung lesions and
she was treated with taxotere followed by herceptin and letrozole. Her disease persisted but she
continued treatment and survived until June 2010.
3. Discussion
The phenomenon of accelerated tumor growth following surgery has been observed repeatedly and
merits further study in order to determine which patients are more likely to encounter this problem. It
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appears that there is more than one clinical manifestation of this occurrence, however, and more than
one mechanism may be involved. Other reports in this symposium [8,9] have found a hormonal
pathogenesis whereby removal of the primary tumor has led to a release of an inhibition on latent
metastases. Another possible mechanism, however, is the stimulation of tumor growth through local
angiogenesis occurring as part of post-traumatic healing. The central importance of tumor
neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast
cancer. Although findings to date have not indicated significant benefits in terms of survival,
nevertheless significant improvements in response rates have been documented [10]. “Surgery-driven
enhancement of metastases”, the subject of a recent review [11] as well as a focus of this symposium,
may well be exemplified by secondary IBC.
IBC is a particularly aggressive form of breast cancer, treated initially with chemotherapy because
of the likelihood of dissemination of micro metastases from the outset. The clinical and pathologic
findings, while differing in extent from patient to patient, are striking and readily apparent to anyone
familiar with this disease. A rapid spread of erythema often with documented invasion of the dermal
lymphatics is pathognomonic of IBC. A diagnosis of inflammatory breast carcinoma is made on the
basis of the clinical findings. A skin biopsy specimen that is negative for dermal lymphatic invasion
does not rule out inflammatory carcinoma [7]. Our experience with the IBC Registry which has
currently enrolled 156 well documented patients with the disease, has confirmed that most patients
present with the sudden appearance of redness, swelling and tenderness of the breast.
One interesting subgroup of patients, however, are the eight patients in our Registry meeting the
case definition of secondary IBC; described by Taylor and Meltzer who noted that “In the group which
we would designate as secondary (IBC) the inflammatory manifestations may appear suddenly in a
breast which has long been the seat of a scirrhous carcinoma…or it may follow mastectomy for
scirrhous carcinoma, either at the original site or the opposite breast” [1]. Our experience with IBC,
noted in the case reports above, suggest that local trauma probably mediated in large part by
angiogenesis can be an important trigger of IBC. As with primary IBC, the clinical presentation is not
uniform, but striking occurrences such as described for IBC patients 13 and 20 clearly link the initial
appearance of IBC to the site of surgical trauma.
In this report, we describe two cases compatible with secondary IBC that have been identified by
our IBC Registry and two cases where IBC appeared at the site of local trauma. In these four cases, the
brief interval between the breast trauma and the appearance of clinical evidence of IBC (Table 1) is
understandable in view of the rapidity with which IBC advances. It is reasonable to hypothesize that
latent cancer cells remain after surgery and usually do not manifest clinical signs unless stimulated by
local angiogenesis. Not only can surgery promote shedding of tumor cells from the malignant tissue
into the blood and lymphatic system but it could also eliminate the distant anti-angiogenic effect
associated with the primary tumor’s presence (carried by factors such as angiostatin and endostatin)
and thus promote the survival of microscopic cancer foci [8]. The tissue damage and subsequent
inflammatory response induced by surgery can also lead to elevation of pro-angiogenic factors and
growth factors (e.g., EGF) [8]. We propose that consideration be given to focusing on possible
parallels between “surgery-driven enhancement of metastases” and secondary IBC to identify
opportunities to further understand the mechanism for this phenomenon.
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Table 1. Date of trauma/ surgery, onset of symptoms, IBC diagnosis and time interval
between trauma and surgery and onset of symptoms.
IBC
ID

13

20

36

46

Date of
Trauma/Surgery

January 2000:
breast
reconstruction

July 2000: partial
mastectomy
December 2000:
Ductogram
performed
January 1999:
nipple piercing,
Ring removal in
December 1999

Onset of Symptoms

Date of IBC Diagnosis

Time Interval (between
Trauma/Surgery and
IBC Symptoms)

Early 2000 (exact month not
specified): redness noted at
the surgical scar site;
Subsequently contralateral
axillary metastasis
(August 2000)

August 2000: recurrence
of breast cancer,
clinically diagnosed as
IBC

Approximately
1–3 months

September 2000: erythema
noted near the surgical scar
site

September 2000: right
breast excision
performed; biopsy
documented dermal
lymphatic invasion

2 months

December 2000

January 2001: Biopsy and
clinical exam

<1 month

December 1999

Clinically, December
1999, confirmed on
biopsy February 2000

Less than one month
between ring removal and
first clinical signs

The possibility that trauma can be etiologically related to cancer is raised primarily by a number of
case reports. In 1933, Coley and Higinbotham reported 360 cases of bone sarcoma, of which 181 (50%)
had histories of trauma, and 205 cases of breast carcinoma of which 70 (34%) were associated with
trauma [12]. An impressive series has suggested trauma as a cause of bone cancer [13], and a review of
post-surgical bone cancers associated with metal implants identified 22 various bone tumors, 17 since
1980 [14]. Several studies have also observed an increased relative risk of carcinoma associated with a
history of nasal trauma or injury [15]. A number of studies have reported brain tumors to be significantly
associated with trauma [16] and the role of angiogenesis in the healing process has been suggested as
an important contribution to tumor aggressiveness [17,18]. This symposium [8,9] follows previous
reports [11,19,20] noting the possible contribution of surgery to aggressive breast cancer, but the major
focus in these reports has been the systemic contribution of excising a tumor to promoting the
acceleration of distant latent micrometastasis [8,9,20].
Surgery remains an effective therapy for solid tumors in the U.S. and dramatically improves
survival rates. Recurrences remain the most important challenge; almost one third of surgical patients
will ultimately recur locally and/or systemically [21]. The attribution of a malignancy/metastasis to
local trauma by searching for a reason for the disease (recall bias) is always a possibility but in view of
the hypothesis that trauma in the form of a surgery can stimulate angiogenesis which can accelerate
tumor growth, the documentation of IBC appearing following a surgical event and precipitated by it
(Case 13 and 20) merits consideration.
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4. Conclusions
The evidence presented in this symposium and in careful reviews [8,9,11] indicating that surgery
can facilitate the appearance of metastatic disease requires considerable attention. While surgery is
clearly an important tool in curing breast cancer and is not questioned in the initial treatment of this
disease, perhaps a discussion of the potential risks of surgery in breast reconstruction is warranted,
particularly if the patient is apparently disease-free after treatment for IBC.
In view of the hypothesis that trauma can stimulate angiogenesis which can accelerate tumor
growth, the documentation of IBC appearing at the site of a traumatic event merits consideration. Our
experience with IBC, noted in the case reports above suggest that local trauma probably mediated in
large part by angiogenesis can be an important trigger of IBC. Studies on human-murine xenograft
models like the Mary-X [22] and WIBC-9 [23] have provided insights on the biology of inflammatory
breast cancer. These models can be used to define our hypothesis of surgically induced angiogenesis
promoting metastasis at the histological and molecular level. We would therefore suggest that
secondary IBC be considered for investigation of one possible mechanism for post-surgical tumor
dissemination. A major question is how to identify patients at increased risk for this possible
complication. Further attention to animal models and a more systematic study of the risk factors in
patients with secondary IBC could be helpful.
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